首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1634158

全球流動止血劑市場 - 2025 - 2032

Global Flowable Hemostats Market - 2025 - 2032

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球可流動止血劑市場達到8.2516億美元，預計到2032年將達到15.2496億美元，在2025-2032年預測期間複合年成長率為7.0%。

可流動止血劑是一種旨在幫助控制外科手術或創傷護理期間出血的醫療產品。它們透過兩種關鍵機制的結合發揮作用，包括提供物理屏障和積極促進人體的自然凝血過程。第一種機制涉及止血材料，例如明膠，用作機械填塞。第二種機制是包含活性成分，如凝血酶，它在啟動凝血級聯中發揮作用。凝血酶透過將纖維蛋白原轉化為纖維蛋白來加速血塊的形成，形成穩定的血塊，有效密封傷口。

可流動止血器的主要優點之一是其多功能性和易用性。這些產品通常呈現液體或凝膠狀形式，使其易於直接塗抹到出血部位，甚至難以觸及或形狀不規則的傷口。它們可以適應各種傷口類型，確保有效控制出血，無論傷口深、窄或位於複雜區域。

市場動態：

驅動程式和限制

外科手術數量不斷增加

全球外科手術數量的增加預計將顯著推動全球可流動止血劑市場。隨著全球人口老化和慢性病的盛行率上升，對手術（從常規手術到更複雜的手術）的需求持續成長。隨著越來越多的人需要針對心血管疾病、癌症和骨科問題進行手術干預，在這些手術過程中有效控制出血的需求變得更加重要。例如，美國國立衛生研究院在 2023 年表示，每年進行近 40 萬例 CABG 手術，使其成為最常進行的主要外科手術。可流動止血器在這種情況下特別有價值，因為它們提供了快速可靠的止血解決方案，這對於確保患者安全和改善手術結果至關重要。

此外，根據世界衛生組織2023年的報告，每年約有119萬人因道路交通事故死亡。道路交通傷害是 5-29 歲兒童和年輕人死亡的主要原因，出血佔可預防死亡的很大一部分，凸顯了可流動止血劑在創傷護理和外科干預中的關鍵作用。

可流動止血劑成本高

可流動止血劑，特別是含有特殊材料或活性成分（如凝血酶）的高級版本，往往比傳統的控制出血方法（如紗布、海綿或手動壓迫）更昂貴。這種成本差異可能會使醫療保健提供者不願意採用可流動止血劑，特別是在成本效益是關鍵考慮因素的情況下。在預算有限的醫院或診所，這些產品的高成本可能會導致人們傾向於選擇更便宜的替代品，即使流動止血劑在速度和有效性方面具有卓越的性能。

Flowable hemostats are medical products designed to help control bleeding during surgical procedures or trauma care. They work through a combination of two key mechanisms which include providing a physical barrier and actively promoting the body's natural clotting process. The first mechanism involves a hemostatic material, such as gelatin, which serves as a mechanical tamponade. The second mechanism is the inclusion of an active component, like thrombin, which plays a role in initiating the clotting cascade. Thrombin accelerates the formation of a blood clot by converting fibrinogen into fibrin, creating a stable clot that effectively seals the wound.

One of the key advantages of flowable hemostats is their versatility and ease of use. These products are typically in a liquid or gel-like form, making them easy to apply directly to bleeding sites, even in difficult-to-reach or irregularly shaped wounds. They can conform to various wound types, ensuring effective bleeding control, whether the wound is deep, narrow, or located in a complex area.

Market Dynamics: Drivers & Restraints

Increasing number of surgical procedures

The increasing number of surgical procedures worldwide is expected to significantly drive the global flowable hemostats market. As the global population ages and the prevalence of chronic conditions rises, the demand for surgeries, ranging from routine procedures to more complex operations continues to grow. With more people needing surgical interventions for conditions like cardiovascular disease, cancer, and orthopedic issues, the need for effective bleeding control during these procedures becomes even more critical. For instance, the National Institute of Health in 2023 stated that almost 400,000 CABG surgeries are performed each year making it the most commonly performed major surgical procedure. Flowable hemostats are especially valuable in this context because they provide a fast and reliable solution to stop bleeding, which is essential for ensuring patient safety and improving surgical outcomes.

Moreover, according to the World Health Organization report in 2023, approximately 1.19 million people die each year as a result of road traffic crashes. Road traffic injuries are the leading cause of death for children and young adults aged 5-29 years with hemorrhage accounting for a significant portion of preventable deaths, underscoring the critical role of flowable hemostats in trauma care and surgical interventions.

High costs of flowable hemostats

Flowable hemostats, particularly advanced versions that contain specialized materials or active components like thrombin, tend to be more expensive than traditional methods of controlling bleeding, such as gauze, sponges, or manual compression. This cost variation can make healthcare providers reluctant to adopt flowable hemostats, especially in settings where cost-effectiveness is a key consideration. In hospitals or clinics with limited budgets, the high cost of these products can result in a preference for cheaper alternatives, even if flowable hemostats offer superior performance in terms of speed and effectiveness.

Segment Analysis

The global flowable hemostats market is segmented based on product, material, application, end-user, and region.

Product:

Active Hemostats segment is expected to dominate the global Flowable Hemostats share

Active hemostats hold a dominant share of the flowable hemostats market due to their ability to directly boost the body's natural clotting process. These products contain bioactive substances, such as thrombin, that accelerate the formation of a stable blood clot by converting fibrinogen into fibrin. This makes active hemostats much more effective at controlling bleeding compared to passive hemostats, which only work through mechanical methods like pressure or absorption.

The strong market presence of active hemostats is also driven by their versatility and superior performance. While passive hemostats are often used for minor bleeding, active hemostats are favored for more serious bleeding scenarios, especially in complex surgeries like cardiovascular, trauma, or orthopedic procedures. Innovations are being unveiled by the top players with the rising demand for active hemostats. For instance, in April 2023, Baxter International Inc. unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023. The innovation also includes the launch of the Floseal + Recothrom flowable hemostat.

As surgical methods become increasingly advanced and minimally invasive, the demand for products that can quickly and effectively address bleeding, even in hard-to-reach areas, continues to rise. This combination of efficiency and versatility ensures that active hemostats continue to dominate the flowable hemostats market.

Geographical Analysis

North America is expected to hold a significant position in the global Flowable Hemostats share

North America is dominant in the global flowable hemostats market due to several key factors that drive demand for advanced bleeding control solutions. The region, particularly the United States, has a highly developed healthcare infrastructure with state-of-the-art hospitals, surgical centers, and research facilities. These medical facilities often perform complex surgeries that require effective bleeding management, making flowable hemostats an essential tool. The strong healthcare system ensures that these products are widely accessible and regularly used across various surgical procedures, from routine operations to high-risk interventions.

The regulatory environment in North America, particularly with regulatory bodies like the FDA, ensures that these products meet stringent quality standards, fostering trust and encouraging their widespread adoption. Furthermore, the region is also experiencing a growing number of surgical procedures, fuelled by an aging population and the rising incidence of chronic diseases like cardiovascular conditions and cancer. For instance, according to the report published by the National Institute of Health in 2023, it is stated that approximately 600,000 hysterectomy procedures are performed annually in the United States (U.S.), making it the most common non-obstetric surgical procedure among women.

As surgeries become more frequent and complex, the demand for effective, easy-to-use hemostatic products continues to rise, further solidifying North America's dominant position in the global flowable hemostats market.

Asia Pacific is at the fastest growing pace in the global flowable hemostats market share

Asia Pacific is currently experiencing the fastest growth in the global flowable hemostats. This is due to the increasing innovation of products that help in early bleeding control. Moreover, the rising prevalence of chronic diseases and an aging population in countries like Japan and China contribute significantly to the increasing number of surgical procedures in the region. With a higher incidence of conditions such as cardiovascular diseases, cancer, and diabetes, the need for complex surgeries and effective blood management solutions is also growing. Flowable hemostats are particularly valuable in these cases due to their ability to provide quick, reliable bleeding control in both traditional and minimally invasive surgeries.

Competitive Landscape

The major global players in the flowable hemostats market include Aegis Lifesciences, Baxter, Teleflex Incorporated, Becton, Dickinson, and Company, Johnson & Johnson Services, Inc., Pfizer Inc., 3-D Matrix Medical Technology, Medcura, Ferrosan Medical Devices A/S and Delta Surgical among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Flowable Hemostats Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Material
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing number of surgical procedures
- 4.1.2. Restraints
  - 4.1.2.1. High costs of flowable hemostats
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Product

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
- 6.1.2. Market Attractiveness Index, By Product
6.2. Active Hemostats*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Passive Hemostats
6.4. Combination Hemostats

7. By Material

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 7.1.2. Market Attractiveness Index, By Material
7.2. Porcine Gelatin*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bovine Gelatin

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. General Surgery*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular Surgery
8.4. Orthopedic Surgery
8.5. Others

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Diagnostic Laboratories
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Aegis Lifesciences*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Baxter
12.3. Teleflex Incorporated
12.4. Becton, Dickinson, and Company
12.5. Johnson & Johnson Services, Inc.
12.6. Pfizer Inc.
12.7. 3-D Matrix Medical Technology
12.8. Medcura
12.9. Ferrosan Medical Devices A/S
12.10. Delta Surgical

LIST NOT EXHAUSTIVE